UPDATE: Stifel Initiates Coverage on Celladon Corporation with Buy Rating, $16 PT as Novel Gene Therapy Could Revolutionize Heart Failure Treatment
In a report published Monday, Stifel analyst Brian Klein initiated coverage on Celladon Corporation (NASDAQ: CLDN) with a Buy rating and $16.00 price target.
In the report, Stifel noted, “We are initiating coverage of Celladon Corporation (CLDN) with a Buy rating and $16 target price. Mydicar is a one-time infusion of a viral vector that transfers a SERCA2a gene into heart muscle cells with the intention of improving calcium regulation and improving function.”
Celladon Corporation closed on Friday at $7.57.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.